PHA 568487

• Description :

  PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) [1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3].

• UNSPSC :

  12352005

• Target :

  NAChR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/pha-568487.html

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  OC(/C=C/C(O)=O)=O.O=C(C1=CC=C(OCCO2)C2=C1)N[C@@H]3C4CCN(CC4)C3

• Molecular Formula :

  C20H24N2O7

• Molecular Weight :

  404.41

• References & Citations :

  [1]F Barclay Shilliday, et al. Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett. 2010 Aug;4 (3) :162-72.|[2]Zhenying Han, et al. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. J Neurochem. 2014 Nov;131 (4) :498-508.|[3]Dingquan Zou, et al.Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture. Mol Neurobiol. 2017 Dec;54 (10) :8278-8286.|[4]Lorena Colás, et al. In vivo imaging of Α7 nicotinic receptors as a novel method to monitor neuroinflammation after cerebral ischemia. Glia. 2018 Aug;66 (8) :1611-1624.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [527680-57-5]